Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.54 |
| ▸ | HTR2C | P28335 | 3/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | HTR1D | P28221 | 8/20 | 0.51 |
| ▸ | HTR7 | P34969 | 4/20 | 0.51 |
| ▸ | NOS3 | P29474 | 3/20 | 0.49 |
| ▸ | NOS1 | P29475 | 3/20 | 0.49 |
| ▸ | BPTF | Q12830 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7252922 | 0.91 | HTR2A (0.64) | HTR2AHTR2CEGFRHTR1DHTR7 | |
| SCHEMBL31258100 | 0.91 | HTR2A (0.64) | HTR2AHTR2CEGFRHTR1DHTR7 | |
| SCHEMBL16741930 | 0.88 | EGFR (0.53) | HTR2AHTR2CEGFRHTR7NOS3 | |
| SCHEMBL18239699 | 0.79 | HTR7 (0.57) | HTR2AHTR2CHTR1DHTR7 | |
| SCHEMBL7256513 | 0.79 | HTR7 (0.51) | HTR2AHTR2CHTR1DHTR7NOS3 | |
| SCHEMBL1049671 | 0.79 | HTR7 (0.51) | HTR2AHTR2CHTR7 | |
| SCHEMBL6990971 | 0.78 | HTR2A (0.50) | HTR2AHTR2CHTR1DNOS3NOS1 | |
| SCHEMBL20540198 | 0.78 | HTR2C (0.61) | HTR2AHTR2CEGFRHTR1DHTR7 | |
| SCHEMBL1121913 | 0.78 | NOS3 (0.53) | HTR2AHTR2CHTR1DNOS3NOS1 | |
| SCHEMBL3990419 | 0.78 | HTR2C (0.81) | HTR2AHTR2CHTR1DNOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6635639-B2 | Treatment or diagnosis of central nervous system conditions | NPS ALLELIX CORP. (CA) | 2003-10-21 | — | — | US | disclosed |
| US-20020169322-A1 | Use of N-alkylamino-heterocylic compounds for the treatment of migraine | NPS ALLEXLIX CORP. | 2002-11-14 | — | — | US | disclosed |
| US-6380242-B1 | FOR DIAGNOSIS AND THERAPY OF CENTRAL NERVOUS SYSTEM CONDITIONS | NPS ALLELIX CORP. (CA) | 2002-04-30 | — | — | US | disclosed |
| EP-1140074-A1 | INDOLE AND INDOLIZIDINE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | NPS Allelix Corp. (CA) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000038677-A1 | INDOLE AND INDOLIZIDINE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169322-A1 | Use of N-alkylamino-heterocylic compounds for the treatment of migraine | CNR1, CNR2, KCNH1 | HTR2A 425/4885HTR2C 127/4885EGFR 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.